Drug General Information (ID: DDIBU5Q38C)
Drug Name			Antithymocyte immunoglobulin (rabbit)		Drug Info		Talimogene laherparepvec		Drug Info
Drug Type		Polyclonal antibody				Vaccine
Therapeutic Class		Antiinflammatory Agents				Anticancer Agents

Mechanism of Antithymocyte immunoglobulin (rabbit)-Talimogene laherparepvec Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Antithymocyte immunoglobulin (rabbit)				Talimogene laherparepvec
Mechanism		Immunosuppressive effects				Vaccine or toxoid
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Talimogene laherparepvec when combined with Antithymocyte immunoglobulin (rabbit)

Recommended Action
Management		Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.

References
1	Product Information. Imlygic (talimogene laherparepvec). Amgen USA, Thousand Oaks, CA.